Skye Bioscience Shares Gain After Highlighting Safety of In-Development Obesity Treatment

Dow Jones09-24
 

By Connor Hart

 

Shares of Skye Bioscience gained after the San Diego biopharmaceutical company released a statement Monday highlighting the safety of its in-development obesity treatment compared with other treatments being developed.

The stock was up 15% to $3.60 in afternoon trading. Shares are up 34% since the beginning of the year.

Skye Bioscience's statement comes after Danish pharmaceutical giant Novo Nordisk on Friday disclosed results from a clinical trial of one of its in-development obesity treatments. The treatment, called monlunabant, achieved a statistically significant weight loss compared to placebo, but users reported mild-to-moderate neuropsychiatric side effects, such as anxiety, irritability and sleep disturbances, Novo Nordisk said.

Skye Bioscience on Monday said this adverse event highlights a difference between its in-development obesity treatment, nimacimab, and Novo Nordisk's monlunabant.

Data from a recent nimacimab trial did not show any adverse neuropsychiatric events in users, which the company attributed to the treatment being a large-molecule CB1 inhibitor rather than a small-molecule CB1 inhibitor.

Chief Scientific Officer Chris Twitty said small-molecule CB1 inhibitors lack adequate restriction from the brain, resulting in an increased potential for neuropsychiatric side effects.

"It is clear that with increased restriction from the brain, nimacimab provides a potential clear safety advantage over a small molecule approach," Chief Executive Officer Punit Dhillon said.

 

Write to Connor Hart at connor.hart@wsj.com

 

(END) Dow Jones Newswires

September 23, 2024 15:11 ET (19:11 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment